Journal: bioRxiv
Article Title: Scalable Human Cellular Models of Parkinson’s Disease Reveal A Druggable Link Between the Angiotensin Receptor 1 and α-Synuclein Pathology
doi: 10.1101/2025.11.18.689137
Figure Lengend Snippet: ( A ) The schematic shows different conditions used for qRT-PCR analysis of synuclein gene expression. ( B-D ) qRT-PCR for SNCA, SNCAIP, and SNCB expression using Ang II (AGTR1 agonist) vs Cand (AGTR1 inhibitor). Significance is shown compared to DMSO and CBE + CAND compared to CBE * p<0.05, **p<0.01. ( E ) Pipeline of survival experiments in 3D mDA-mAstro assembloids. CBE treatment followed by AGTR1 inhibitors (sartans) was performed at D60 for 14 days. ( F, G ) CBE treatment increases the number of mDA neurons that are positive for p129-αSYN, a hallmark of PD. Treatment with Candesartan or Valsartan mitigates the number of p129αSYN positive cells. (mDA-mAstro assembloids from 3 independent differentiations). Significance is shown compared to the CBE condition. **p<0.01, *** p<0.001. Scale bars: 200μm (100μm in zoomed images)
Article Snippet: Primers were ordered from predesigned Taqman PCR assays (Thermofisher) with the following catalog numbers: (GAPDH: Hs02786624_g1; SNCA: Hs00240906_m1; SNCB: Hs01015410_g1; SNCAIP: Hs00917422_m1).
Techniques: Quantitative RT-PCR, Gene Expression, Expressing